Phenotypes Associated with This Genotype

Genotype
MGI:7767823

cn32

• Allelic Composition: Osbpl3^{tm1c(EUCOMM)Wtsi}/Osbpl3^{tm1c(EUCOMM)Wtsi}; Tg(KRT14-cre)1Amc/0
• Genetic Background: involves: C57BL/6 * C57BL/6N * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

neoplasm ( J:341532 )

N • untreated mice do not develop tumors over a period of 2 years

increased incidence of tumors by chemical induction ( J:341532 )

• mice show a 5-fold increase in the incidence of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced invasive bladder carcinomas relative to BBN-treated control mice (38.9% versus 7.7%, respectively)

abnormal tumor pathology ( J:341532 )

• after BBN treatment, only 5.5% of bladder tissue is normal versus 38.4% in BBN-treated control mice

• however, the incidence of carcinoma in situ is not significantly changed after BBN treatment (33.3% versus 30.8% in control mice), suggesting that Osbpl3 impairs the progression of tumors towards invasive carcinoma

decreased tumor latency ( J:341532 )

• BBN-treated mice typically develop invasive bladder carcinomas earlier than BBN-treated control mice

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:341532 )

• mice show a 5-fold increase in the incidence of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced invasive bladder carcinomas relative to BBN-treated control mice (38.9% versus 7.7%, respectively)